A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies

Jinbin Zhai1, James B Papizan1, Yu Yao2

  • 1Center for Advanced Genome Engineering, Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN.

Blood Advances
|August 27, 2025
PubMed

Insights

Researchers developed a new mouse model for sickle cell disease (SCD) HbSC, a common form of SCD. This model mimics human HbSC pathologies, advancing research for this understudied SCD type.

Area of Science:

  • Genetics and Genomics
  • Hematology
  • Disease Modeling

Background:

  • Sickle cell disease (SCD) is a group of inherited blood disorders caused by mutations in the beta-globin gene (HBB).
  • The most common form, HbSS, has well-established mouse models, but research on the second most common form, HbSC, is limited by a lack of suitable animal models.
  • HbSC arises from distinct HBB mutations (p.Glu6Val/p.Glu6Lys) compared to HbSS (p.Glu6Val).

Purpose of the Study:

  • To create and characterize a novel mouse model for HbSC, the second most prevalent form of sickle cell disease.
  • To enable further investigation into the unique pathological mechanisms of HbSC disease.
  • To facilitate the development of targeted therapies for HbSC.

Main Methods:

  • Utilized CRISPR genome engineering to introduce HbSC mutations into the Townes mouse strain.
  • The Townes strain contains human alpha- and beta-globin genes, replacing the mouse counterparts.
  • Phenotypic analysis of the generated HbSC mice was performed and compared to Townes HbSS mice.

Main Results:

  • Successfully generated mice carrying the HbSC alleles using CRISPR technology.
  • HbSC mice displayed distinct pathological features mirroring those observed in human HbSC patients.
  • These pathologies differed from those observed in the Townes HbSS mouse model.

Conclusions:

  • The developed HbSC mouse model accurately recapitulates key aspects of human HbSC disease.
  • This new model provides a valuable tool for studying HbSC pathophysiology and testing therapeutic interventions.
  • It addresses a critical gap in animal models for SCD research, specifically for the HbSC variant.